Dosing and uses of Nevanac, Ilevro (nepafenac ophthalmic)
Adult dosage forms and strengths
ophthalmic suspension
- 0.1%
- 0.3%
Ocular Pain & Inflammation
Indicated for pain and inflammation associated with cataract surgery
0.1%: 1 gtt TID to affected eye(s) beginning 1 day before cataract surgery, on the day of surgery and through 2 weeks postoperatively
0.3%: 1 gtt once daily beginning 1 day before cataract surgery, on day of surgery, and continue through the first 2 weeks postoperatively; an additional drop should be adminsitered 30-120 minutes before surgery
Administration
Do not wear contact lenses while using
Shake well before using
Pediatric dosage forms and strengths
<10 years old: Safety and efficacy not established
Nevanac, Ilevro (nepafenac ophthalmic) adverse (side) effects
1-10%
Capsular opacity
Decr visual acuity
Foreign body sensation
Increased IOp
Sticky sensation
Conjunctival edema
Corneal edema
Dry eye
Headache
HTn
Lid margin crusting
N/V
Ocular discomfort
Ocular hyperemia
Ocular pain
Ocular pruritus
Photophobia
Tearing
Vitreous detachment
Warnings
Contraindications
Hypersensitivity to NSAIDs or any ingredients
Cautions
Sensitivity to aspirin or phenylacetic acid deivatives
May cause incr bleeding in ocular tissues
May cause keratitis & corneal damage (risk incr if applied earlier than 1 day presurgery or longer than 2 wk postsurgery)
Pregnancy and lactation
Pregnancy category: C
Lactation: use caution
Pregnancy categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA: Information not available.
Pharmacology of Nevanac, Ilevro (nepafenac ophthalmic)
Mechanism of action
Non-steroidal anti-inflammatory prodrug, converted to amfenac which putatively inhibits prostaglandin biosynthesis
Absorption
Absoption: Low systemic absorption
Peak Plasma: nepafenac 0.31 ng/mL; amfenac: 0.42 ng/mL
